Erratum: Economic analysis of human papillomavirus triage, repeat cytology, and immediate colposcopy in management of women with minor cytological abnormalities in Sweden (Acta Obstetricia et Gynecologica (2010) 89:10 (1316-1325) (DOI: 10.3109/00016349.2010.512066);Economic analysis of human papillomavirus triage, repeat cytology, and immediate colposcopy in management of women with minor cytological abnormalities in Sweden

Acta Obstetricia et Gynecologica Scandinavica

Volumn 89, Issue 10, 2010, Pages 1316-1325

  Stensson, Ellinor ^a   Frberg, Maria ^a   Hjerpe, Anders ^a   Zethraeus, Niklas ^b   Andersson, Sonia ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cost effectiveness; Healthcare policy; Human papillomavirus (HPV) triage; Incremental cost effectiveness ratio (ICER); Screening

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; COLPOSCOPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONHUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; REPEAT PROCEDURE; SWEDEN; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; WART VIRUS;

EID: 77956869356     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.3109/00016349.2010.531177     Document Type: Erratum

References (30)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24: 2137-2150
2. Gunnell AS, Ylitalo N, Sandin S, Sparen P, Adami HO, Ripatti S. A longitudinal Swedish study on screening for squamous cell carcinoma and adenocarcinoma: evidence of effectiveness and overtreatment. Cancer Epidemiol Biomarkers Prev. 2007;16:2641-2648
3. Kinney WK, Manos MM, Hurley LB, Ransley JE. Wheres the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol. 1998;91: 973-976
4. Silfverdal L, Kemetli L, Andrae B, Sparen P, Ryd W, Dillner J, et al. Risk of invasive cervical cancer in relation to management of abnormal Pap smear results. Am J Obstet Gynecol. 2009;201:188 e1-7.
5. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008; 337:a1284.
6. Chase DM, Kalouyan M, DiSaia PJ. Colposcopy to evaluate abnormal cervical cytology in 2008. Am J Obstet Gynecol. 2009;200:472-480
7. Freeman-Wang T, Walker P, Linehan J, Coffey C, Glasser B, Sherr L. Anxiety levels in women attending colposcopy clinics for treatment for cervical intraepithelial neoplasia: a randomised trial of written and video information. BJOG. 2001;108:482-484
8. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;24(Suppl 3):S3.
9. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008;26 (Suppl 10):K29-41.
10. Andersson S, Dillner L, Elfgren K, Mints M, Persson M, Rylander E. A comparison of the human papillomavirus test and Papanicolaou smear as a second screening method for women with minor cytological abnormalities. Acta Obstet Gynecol Scand. 2005;84:996-1000.
11. Solomon D, Davey D, Kurman R, Moriarty A, OConnor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287: 2114-2119
12. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin- Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst. 2004;96:280-293 (Pubitemid 38256273)
13. Arbyn M, Martin-Hirsch P, Buntinx F, Van Ranst M, Paraskevaidis E, Dillner J. Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med. 2009;13: 648-659
14. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for highgrade CIN: an update of pooled evidence. Gynecol Oncol. 2005;99(3 Suppl 1):S7-11.
15. Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making. 1994;14:259-265
16. Sparén P. Gynekologisk cellprovskontroll i Sverige-Rapport 2007. Stockholm: Karolinska Institutet, 2008.
17. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9: 425-434
18. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12:186-192
19. Guyot A, Karim S, Kyi MS, Fox J. Evaluation of adjunctive HPV testing by Hybrid Capture II in women with minor cytological abnormalities for the diagnosis of CIN2/3 and cost comparison with colposcopy. BMC Infect Dis. 2003;3:23.
20. Sheriff SK, Petry KU, Ikenberg H, Crouse G, Mazonson PD, Santas CC. An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany. Eur J Health Econ. 2007; 8:153-160
21. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA. 2002;287:2382-2390
22. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst. 2005; 97:888-895
23. Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, et al. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst. 2006;98:92-100.
24. Froberg M, Johansson B, Hjerpe A, Andersson S. Human papillomavirus reflex' testing as a screening method in cases of minor cytological abnormalities. Br J Cancer. 2008;99:563-568
25. Brismar-Wendel S, Froberg M, Hjerpe A, Andersson S, Johansson B. Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions. Br J Cancer. 2009;101:511-517
26. Cantor SB, Mitchell MF, Tortolero-Luna G, Bratka CS, Bodurka DC, Richards-Kortum R. Cost-effectiveness analysis of diagnosis and management of cervical squamous intraepithelial lesions. Obstet Gynecol. 1998;91:270-277
27. Johnson N, Sutton J, Thornton JG, Lilford RJ, Johnson VA, Peel KR. Decision analysis for best management of mildly dyskaryotic smear. Lancet. 1993;342:91-96
28. Myers ER, McCrory DC, Subramanian S, McCall N, Nanda K, Datta S, et al. Setting the target for a better cervical screening test: characteristics of a cost-effective test for cervical neoplasia screening. Obstet Gynecol. 2000;96(5 Pt 1): 645-652
29. Smith WJ. The cost-effectiveness of cervical screening. Curr Opin Obstet Gynecol. 1999;11:83-85
30. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Hansson BG, et al. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer. 2007;97:129-132